Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
about
Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of AntiretroviralsDoravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.When could new antiretrovirals be recommended for national treatment programmes in low-income and middle-income countries: results of a WHO Think Tank.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Why Did I Stop? Barriers and Facilitators to Uptake and Adherence to ART in Option B+ HIV Care in Lilongwe, Malawi.An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3'-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS PatientsChoice of antiretroviral drugs for continued treatment scale-up in a public health approach: what more do we need to know?Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 StudyThe impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenTowards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Role of Cytochrome P450 2B6 Pharmacogenomics in Determining Efavirenz-Mediated Central Nervous System Toxicity, Treatment Outcomes, and Dosage Adjustments in Patients with Human Immunodeficiency Virus Infection.Treating HIV Infection in the Central Nervous System.Validation of Computational Approaches for Antiretroviral Dose OptimizationImpact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Developing and Using Therapeutics for Emerging Infections.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy.Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz.
P2860
Q28069383-64DC2D52-5F80-499E-80B3-4BF874570D5FQ30373063-D51F5060-4163-4217-B59D-A6B4D5092AD7Q33765196-BC151E27-BC6C-4930-8B46-F5A51BDA7506Q34536677-3F6CEAA0-87A9-4376-B5FD-4AF5BA978BDAQ35931175-05F90DFB-5C1E-4577-8460-B9094BC4A67BQ36437792-101BAAD5-1005-4A8D-A47C-621489CF1942Q36541070-086A487B-5B65-46EB-AA5A-CE09C3042826Q37026878-A934071B-9BAB-4120-8DAB-8BD2529DEB42Q37030715-7AB36D7D-6502-4591-85A7-DBB34891278FQ37126489-C3429AB3-A059-4338-B519-796C14A47D96Q37519804-153C6FBA-52B9-4054-8A47-A13C303214A9Q38954109-B0B62173-6076-4C00-9057-AC156440BB8AQ38957969-374F05CE-D5B0-44B7-AF61-3D2E34972FA5Q38990321-D00B2EF9-FC41-48D1-809E-CBB9ABBEFB77Q39077816-457DD0D4-37F6-4AE5-A6BE-3DB656E2DCD8Q39863986-BFF0AC46-F0C0-47EE-8CF8-76B1A7A12A83Q40118824-516AA8D2-F055-491A-8654-A7112A83BCC0Q44099540-C3CD16F5-40BF-4CC4-92C4-4FBFD0CDE3BDQ46460183-752A0FAA-C7ED-4164-82DD-325BE1AA836AQ46600089-834DCE5A-9B7A-45E7-A071-45579ED0C581Q47117336-4186945B-4C64-4D4A-BCBE-A0CF791E0117Q47664709-278DBA48-F6AA-4B63-95D6-ABD85DEB7762Q52330065-705E8B1C-3AA1-4EAF-BD07-C60A66B12B72Q54915406-D1507CA5-1DB8-4CEF-865E-2A20BB5F8710
P2860
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@ast
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@en
type
label
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@ast
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@en
prefLabel
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@ast
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@en
P2093
P2860
P50
P356
P1476
Pharmacokinetic and Pharmacody ...... Results of the ENCORE1 Study.
@en
P2093
D A Cooper
ENCORE1 Study Group
L Dickinson
P2860
P304
P356
10.1002/CPT.156
P407
P577
2015-06-05T00:00:00Z